AtriCure Inc. (ATRC)
NASDAQ: ATRC
· Real-Time Price · USD
35.69
0.92 (2.65%)
At close: Sep 04, 2025, 11:09 AM
2.65% (1D)
| Bid | 35.65 |
| Market Cap | 1.77B |
| Revenue (ttm) | 499.95M |
| Net Income (ttm) | -36.36M |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -46.35 |
| Forward PE | -164.95 |
| Analyst | Buy |
| Ask | 35.73 |
| Volume | 48,331 |
| Avg. Volume (20D) | 508,217 |
| Open | 34.94 |
| Previous Close | 34.77 |
| Day's Range | 34.52 - 35.69 |
| 52-Week Range | 25.50 - 43.11 |
| Beta | 1.62 |
About ATRC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATRC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATRC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
AtriCure Inc. is scheduled to release its earnings on
Oct 28, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+10.72%
AtriCure shares are trading higher after the compa...
Unlock content with
Pro Subscription
1 month ago
-4.49%
AtriCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.
2 weeks ago · businesswire.com
AtriCure to Participate in the 2025 Wells Fargo Healthcare ConferenceMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
1 month ago · fool.com
AtriCure (ATRC) Q2 Revenue Jumps 17%AtriCure (ATRC) Q2 Revenue Jumps 17%
